<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03775473</url>
  </required_header>
  <id_info>
    <org_study_id>PROCODE</org_study_id>
    <nct_id>NCT03775473</nct_id>
  </id_info>
  <brief_title>PROgastrine COlon DEpistage</brief_title>
  <official_title>Dosage of Progastrin in Asymptomatic Person Participating in Colon Cancer Screening</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ECS-Progastrin SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Hospitalier Princesse Grace</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ECS-Progastrin SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dosage of progastrin in asymptomatic person participating in colon cancer screening
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For anyone who will participate in colon screening at the Princess Grace Hospital of Monaco
      and who has signed the informed consent document. A blood test will be performed in addition
      to the screening test to assess the rate of progastrin.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 7, 2019</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Interventional Research, at Risk and Minimal Constraints, Category 2</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progastrin rate</measure>
    <time_frame>from 15 days to 2 months (until results are obtained)</time_frame>
    <description>measuring the rate of progastrin in the blood</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1100</enrollment>
  <condition>Colon Cancer Screening</condition>
  <condition>Healthy Person</condition>
  <arm_group>
    <arm_group_label>progastrin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>anyone who will participate in colon screening at the Princess Grace Hospital in Monaco and who has signed the informed consent document</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>progastrin</intervention_name>
    <description>PROCODE is an interventional study of category 2 (non-medicinal product), with a minimal risks and restrictions, involving only one blood drawn at the screening of colon cancer.</description>
    <arm_group_label>progastrin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  participant in colon cancer screening

          -  signing informed consent

        Exclusion Criteria:

          -  any major medical, psychiatric or addictive illness that would affect the informed
             consent process

          -  The consent of a representative is not allowed in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Georges GARNIER</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Princesse Grace</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Georges Pr GARNIER</last_name>
    <phone>+377 97 98 84 29</phone>
    <email>recherche.clinique@chpg.mc</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mélina BLAIRVACQ, Référent</last_name>
    <phone>0467798230</phone>
    <email>m.blairvacq@eurobiodev.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Princesse Grace</name>
      <address>
        <city>Monaco</city>
        <state>MC</state>
        <zip>98012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BLAIRVACQ MELINA, ARC</last_name>
      <phone>04.67.79.82.30</phone>
      <email>m.blairvacq@eurobiodev.com</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>December 7, 2018</study_first_submitted>
  <study_first_submitted_qc>December 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2018</study_first_posted>
  <last_update_submitted>March 6, 2019</last_update_submitted>
  <last_update_submitted_qc>March 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>progastrin</keyword>
  <keyword>screening</keyword>
  <keyword>bio-marker</keyword>
  <keyword>healthy person</keyword>
  <keyword>early stage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Monocentric study; No IPD sharing</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

